Axsome Therapeutics, Inc. - Common Stock (AXSM)
114.00
+1.08 (0.96%)
Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of central nervous system (CNS) disorders
The company’s research is centered on addressing some of the most challenging conditions in mental health and neurological disorders, including depression, migraine, and Alzheimer’s disease. Axsome is dedicated to advancing its pipeline of drug candidates through rigorous clinical trials with the goal of providing new and effective treatment options to patients and improving their quality of life. Through its commitment to science and patient care, Axsome aims to make significant contributions to the field of CNS therapeutics.
Previous Close | 112.92 |
---|---|
Open | 113.49 |
Bid | 112.00 |
Ask | 115.00 |
Day's Range | 112.00 - 114.00 |
52 Week Range | 64.11 - 114.00 |
Volume | 866,571 |
Market Cap | 5.38B |
PE Ratio (TTM) | -25.62 |
EPS (TTM) | -4.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 969,297 |
News & Press Releases
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQAXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · January 31, 2025
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
By Axsome Therapeutics, Inc. · Via GlobeNewswire · January 30, 2025
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQAXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · January 22, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · November 12, 2024
![](https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg)
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via Investor's Business Daily · January 17, 2025
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively
By Axsome Therapeutics, Inc. · Via GlobeNewswire · January 13, 2025
![](https://cdn.benzinga.com/files/images/story/2024/12/31/AXSM.png?width=1200&height=800&fit=crop)
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.
Via Benzinga · December 31, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Via Benzinga · October 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Via Benzinga · September 9, 2024
![](https://www.investors.com/wp-content/uploads/2024/02/Stock-AxsomeTherapeutics-02-adobe.jpg)
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
Via Investor's Business Daily · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/30/Tesla-Model-3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
By Axsome Therapeutics, Inc. · Via GlobeNewswire · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/27/Contagious-Sleepiness-Effect.jpeg?width=1200&height=800&fit=crop)
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.
Via Benzinga · November 27, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint)
By Axsome Therapeutics, Inc. · Via GlobeNewswire · November 26, 2024
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
AXSM earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 12, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth
By Axsome Therapeutics, Inc. · Via GlobeNewswire · November 12, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQAXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · November 8, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQAXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · October 29, 2024
![](https://g.foolcdn.com/editorial/images/794517/light-bulb-question-marks-woman.jpg)
Yes, bargains can still be found in the stock market.
Via The Motley Fool · October 19, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQAXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
By Axsome Therapeutics, Inc. · Via GlobeNewswire · October 15, 2024
![](https://g.foolcdn.com/editorial/images/791768/physician-giving-medicine-to-elderly-patient.jpg)
It could be an industry giant in the making.
Via The Motley Fool · September 29, 2024
![](https://ml.globenewswire.com/media/fb41e4f1-1df6-4dbd-8fd7-a02f94b7ae4c/small/axsome-logo-png.png)
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders
By Axsome Therapeutics, Inc. · Via GlobeNewswire · September 24, 2024